From CNBC.com…
An influential Food and Drug Administration advisory committee on Friday resoundingly rejected a plan to administer booster shots of Pfizer and BioNTech’s Covid-19 vaccine to the general public, saying they needed more data.
The panel, however, could still clear the shots for older populations. Scientists continued debating the need for a third dose of the vaccines for older populations after their initial vote, leaving open the possibility of other votes.
“It’s likely beneficial, in my opinion, for the elderly, and may eventually be indicated for the general population. I just don’t think we’re there yet in terms of the data,” Dr. Ofer Levy, a vaccine and infectious disease specialist at Boston Children’s Hospital, said after voting against the original proposal. The final tally failed 16-2.
Pfizer’s stock was down more than 1% in intraday trading after the initial vote. Shares of BioNTech were down more than 4%.
